Receptors for regulatory peptides are overexpressed in a variety of human cancers. They
represent the molecular basis for in vivo imaging with radiolabeled peptide probes …

Radiolabeled peptides targeted against receptors on the cell surface have been shown to
be remarkably specific and effective in the diagnosis and therapy of malignant disease …

Receptor targeting with radiolabelled peptides has become very important in nuclear
medicine and oncology in the past few years. The overexpression of many peptide receptors …

Molecular imaging plays an essential role in balancing the clinical benefits and risks of
radionuclide-based cancer therapy. To effectively treat individual patients, careful …

In the 1980s, the 111In-labeled somatostatin analog OctreoScan (Covidien, Hazelwood,
MO) was developed for imaging of somatostatin receptor subtype 2 (sst2) overexpressing …

Regulatory peptides are small, readily diffusable and potent natural substances with a wide
spectrum of receptor-mediated actions in humans. High affinity receptors for these peptides …

On their plasma membranes, cells express receptor proteins with high affinity for regulatory
peptides, such as somatostatin. Changes in the density of these receptors during disease …

Peptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment
for neuroendocrine tumors (NETs) if curative surgery is not an option. A majority of NETs …

On their plasma membranes, cells express receptor proteins with high affinity for regulatory
peptides, such as somatostatin. Changes in the density of these receptors during disease …

Human cancer cells overexpress many peptide receptors as molecular targets.
Radiolabeled peptides that bind with high affinity and specificity to the receptors on tumor …